← Issue №12/ week of Sep 20, 2026/ the whole section, in full

Motility, in full.

All 1 Motility paper in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 1, in full

most clinically useful first
Motility prospective cohort · n=685 · Sep 18, 2026 · Am J Gastro · IF 9.8

Comparison of demographic, clinical, and psychological characteristics among patients with irritable bowel syndrome meeting the Rome clinical, Rome V, and Rome IV criteria.

New evidenceIBSepidemiology
Clinical takeawayConsider Rome clinical criteria for IBS diagnosis in patients with symptoms suggestive of IBS but not meeting Rome V duration or frequency thresholds, as they capture a clinically similar population. Refer to the source for specific criteria thresholds.
What it foundRome clinical criteria identified 533 (77.8%) of suspected IBS patients, missing 20.3% of Rome V-defined cases due to insufficient symptom duration (51.1%) or frequency (48.9%), with comparable symptom severity and psychological burden to Rome V-only patients. The Rome clinical criteria thresholds for symptom duration and frequency are not specified in the abstract.
ContextChallenges the exclusivity of Rome V criteria by showing Rome clinical criteria identify a broader, equally symptomatic IBS population, refining diagnostic inclusivity. Study conducted in consecutive adults with suspected IBS at a tertiary outpatient clinic in China.
Refinessuggested applicable standard· American Gastroenterological Association, Chey WD, Hashash JG, Manning L, Chang L. "AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review." Gastroenterology. 2022;162(6):1737-1745 (doi:10.1053/j.gastro.2021.12.248; PMID 35337654)

Decision at stakeidentifying IBS patients who may benefit from the low-FODMAP diet

The low-FODMAP diet is currently the most evidence-based diet intervention for IBS and is delivered as a structured 3-phase protocol, NOT lifelong restriction: (1) restriction of high-FODMAP foods lasting NO MORE than 4-6 weeks, (2) reintroduction of FODMAP foods, and (3) personalization based on reintroduction results.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Per AGA best practice advice: dietary intervention is most appropriate for IBS patients who have insight into meal-related symptoms and are motivated to make dietary changes. Soluble fiber (e.g., psyllium/ispaghula) is efficacious for global IBS symptoms and is a reasonable initial option, most suitable in constipation-predominant IBS; insoluble fiber (wheat bran) is NOT. The low-FODMAP diet is currently the most evidence-based diet intervention for IBS and is delivered as a structured 3-phase protocol, NOT lifelong restriction: (1) restriction of high-FODMAP foods lasting NO MORE than 4-6 weeks, (2) reintroduction of FODMAP foods, and (3) personalization based on reintroduction results. Any specific diet intervention should be attempted for a predetermined length of time; if there is no clinical response, the diet should be ABANDONED and a different diet or therapy tried, rather than continued indefinitely. Refer willing and appropriate patients to a GI registered dietitian nutritionist (RDN) to implement and supervise the diet. Poor candidates for restrictive diet interventions include patients who already consume few culprit foods, those at risk for malnutrition, those who are food insecure, and those with an eating disorder or uncontrolled psychiatric disorder; routine screening for disordered eating/eating disorders by careful dietary history is critical before starting a restrictive diet.

American Gastroenterological Association, Chey WD, Hashash JG, Manning L, Chang L. "AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review." Gastroenterology. 2022;162(6):1737-1745 (doi:10.1053/j.gastro.2021.12.248; PMID 35337654) · reviewed 2026-07-19 ↗
Wu J … Liu X · American Journal of Gastroenterology · IF 9.8 · PubMed ↗Permalink
← Back to issue №12 Every section of this issue is one click away, at the top of this page. Follow Motility by RSS